CY1110931T1 - Μεθοδος αγωγης της ανωμαλης κυτταρικης αναπτυξεως - Google Patents
Μεθοδος αγωγης της ανωμαλης κυτταρικης αναπτυξεωςInfo
- Publication number
- CY1110931T1 CY1110931T1 CY20101101055T CY101101055T CY1110931T1 CY 1110931 T1 CY1110931 T1 CY 1110931T1 CY 20101101055 T CY20101101055 T CY 20101101055T CY 101101055 T CY101101055 T CY 101101055T CY 1110931 T1 CY1110931 T1 CY 1110931T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- abnormal cell
- cell development
- mammals
- ylamine
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000011712 cell development Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 abstract 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74276605P | 2005-12-05 | 2005-12-05 | |
| US86463706P | 2006-11-07 | 2006-11-07 | |
| EP06820997A EP1959955B1 (en) | 2005-12-05 | 2006-11-23 | Method of treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110931T1 true CY1110931T1 (el) | 2015-06-10 |
Family
ID=38123250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101101055T CY1110931T1 (el) | 2005-12-05 | 2010-11-24 | Μεθοδος αγωγης της ανωμαλης κυτταρικης αναπτυξεως |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7825137B2 (https=) |
| EP (1) | EP1959955B1 (https=) |
| JP (1) | JP4619346B2 (https=) |
| KR (1) | KR101026676B1 (https=) |
| AR (1) | AR056832A1 (https=) |
| AT (1) | ATE488237T1 (https=) |
| AU (1) | AU2006323027B2 (https=) |
| BR (1) | BRPI0619424B1 (https=) |
| CA (1) | CA2632286C (https=) |
| CY (1) | CY1110931T1 (https=) |
| DE (1) | DE602006018354D1 (https=) |
| DK (1) | DK1959955T3 (https=) |
| IL (1) | IL191471A (https=) |
| NZ (1) | NZ568654A (https=) |
| PL (1) | PL1959955T3 (https=) |
| PT (1) | PT1959955E (https=) |
| RU (1) | RU2384331C2 (https=) |
| SI (1) | SI1959955T1 (https=) |
| TW (1) | TWI321050B (https=) |
| WO (1) | WO2007066187A2 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122020017756B1 (pt) * | 2004-08-26 | 2022-02-15 | Pfizer Inc | Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero |
| HRP20130719T1 (en) * | 2005-08-24 | 2013-09-30 | Eisai R&D Management Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (3) |
| KR101146852B1 (ko) * | 2005-12-05 | 2012-05-16 | 화이자 프로덕츠 인크. | Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체 |
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| EP2450437B1 (en) | 2006-04-14 | 2017-05-17 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| CA2661333C (en) * | 2006-08-23 | 2014-08-05 | Eisai R&D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| JP2009132660A (ja) * | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| JP2009203226A (ja) * | 2008-01-31 | 2009-09-10 | Eisai R & D Management Co Ltd | ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤 |
| WO2009103061A2 (en) * | 2008-02-15 | 2009-08-20 | The Children's Hospital Of Philadelphia | Methods and compositions for identifying, diagnosing, and treating neuroblastoma |
| US20110206691A1 (en) * | 2008-02-15 | 2011-08-25 | Mosse Yael P | Methods and Compositions for Treating Neuroblastoma |
| US20100311972A1 (en) * | 2008-02-18 | 2010-12-09 | Mitsuo Nagai | Method for producing phenoxypyridine derivative |
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
| WO2010064300A1 (ja) * | 2008-12-02 | 2010-06-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 食道癌治療用組成物 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009004061A1 (de) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| AU2010344973B2 (en) | 2010-02-05 | 2016-06-16 | Merck Patent Gmbh | Hetaryl-[1,8]naphthyridine derivatives |
| WO2011100502A1 (en) * | 2010-02-11 | 2011-08-18 | OSI Pharmaceuticals, LLC | 7-aminofuropyridine derivatives |
| EP2566858A2 (en) | 2010-05-04 | 2013-03-13 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| WO2011162343A1 (ja) | 2010-06-25 | 2011-12-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
| MX2012014537A (es) | 2010-07-05 | 2013-02-21 | Merck Patent Gmbh | Derivados de bipiridilo utiles para el tratamiento de enfermedades inducidas por cinasa. |
| US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
| EP2680843A4 (en) * | 2011-03-03 | 2015-05-06 | Concert Pharmaceuticals Inc | DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS |
| US9145390B2 (en) | 2011-03-03 | 2015-09-29 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| MX2013010163A (es) | 2011-03-09 | 2013-10-30 | Merck Patent Gmbh | Derivados de pirido[2,3-b] pirazina y sus usos terapeuticos. |
| EP2758387A4 (en) * | 2011-09-21 | 2015-03-11 | Teligene Ltd | Pyridine compounds as kinase inhibitors |
| RS55728B1 (sr) | 2012-01-31 | 2017-07-31 | Daiichi Sankyo Co Ltd | Derivat piridona |
| HUE034118T2 (en) | 2012-03-06 | 2018-01-29 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| WO2013148537A1 (en) * | 2012-03-29 | 2013-10-03 | Ning Xi | Substituted spirobicyclic compounds and methods of use |
| DK2838998T3 (en) | 2012-04-18 | 2018-01-15 | Cell Signaling Technology Inc | EGFR AND ROS1 IN CANCER |
| CN103509008A (zh) * | 2012-06-22 | 2014-01-15 | 康瑟特制药公司 | 吡唑取代的氨基-杂芳基化合物的衍生物 |
| WO2014020467A2 (en) | 2012-07-30 | 2014-02-06 | Fresenius Kabi Oncology Ltd | Process for the preparation of pyrazole substituted aminoheteroaryl compounds |
| CN104603620B (zh) | 2012-09-24 | 2018-02-23 | 文塔纳医疗系统公司 | 使用间变性淋巴瘤激酶(alk)作为标志物鉴定治疗响应性非小细胞肺癌的方法 |
| BR112015010221B1 (pt) * | 2012-11-06 | 2022-09-13 | Shanghai Fochon Pharmaceutical Co., Ltd. | Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| EA201201654A1 (ru) * | 2012-12-28 | 2014-06-30 | Ооо "Эн.Си.Фарм" | Противоопухолевое средство (варианты) |
| WO2014115169A2 (en) * | 2013-01-24 | 2014-07-31 | Hetero Research Foundation | Crizotinib solid dispersion |
| EP2958592A1 (en) | 2013-02-22 | 2015-12-30 | F. Hoffmann-La Roche AG | Methods of treating cancer and preventing drug resistance |
| EP2968167A1 (en) * | 2013-03-13 | 2016-01-20 | ratiopharm GmbH | Dosage form comprising crizotinib |
| EP2997377B1 (en) | 2013-05-14 | 2018-07-18 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| JP6291179B2 (ja) * | 2013-07-26 | 2018-03-14 | 関東化學株式会社 | 光学活性２級アルコールの製造方法 |
| WO2015036898A2 (en) * | 2013-09-10 | 2015-03-19 | Shilpa Medicare Limited | Novel salts of crizotinib and their preparation |
| RU2550346C2 (ru) | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| WO2015069922A2 (en) | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| TWI690525B (zh) | 2014-07-07 | 2020-04-11 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| CA2955676A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| AU2016224583B2 (en) | 2015-02-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| CA3000386A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| US12066428B2 (en) * | 2015-11-20 | 2024-08-20 | Agilent Technologies, Inc. | Cell-substrate impedance monitoring of cancer cells |
| WO2017201502A1 (en) | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
| GB201616116D0 (en) * | 2016-09-22 | 2016-11-09 | Astrazeneca Ab | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| EP3624800A4 (en) | 2017-05-16 | 2021-02-17 | Eisai R&D Management Co., Ltd. | TREATMENT OF HEPATOCELLULAR CARCINOMA |
| CN108047231B (zh) * | 2018-01-02 | 2020-02-11 | 江苏医药职业学院 | [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用 |
| IT201800003875A1 (it) | 2018-03-22 | 2019-09-22 | Metis Prec Medicine Sb S R L | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| EP4725489A2 (en) | 2019-08-02 | 2026-04-15 | OneHealthCompany, Inc. | Treatment of canine cancers |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725601A (en) | 1985-06-04 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers |
| GB9201693D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
| JPH07109260A (ja) | 1993-10-12 | 1995-04-25 | Fuji Photo Film Co Ltd | ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法 |
| MX9707453A (es) * | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| SE9700661D0 (sv) | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
| SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| PL215901B1 (pl) * | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
| AU5636900A (en) * | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CN1231473C (zh) * | 2000-02-16 | 2005-12-14 | 神经能质公司 | 取代的芳基吡嗪 |
| GB0101577D0 (en) * | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| US6992087B2 (en) * | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| CA2517256C (en) * | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| WO2005026129A1 (en) * | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| AU2004319815A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| ME01309B (me) * | 2004-08-26 | 2013-12-20 | Pfizer | Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza |
| BR122020017756B1 (pt) * | 2004-08-26 | 2022-02-15 | Pfizer Inc | Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero |
| BRPI0514687A (pt) * | 2004-08-26 | 2008-06-17 | Pfizer | compostos amino heteroarila como inibidores de proteìna tirosina cinase |
| KR101146852B1 (ko) * | 2005-12-05 | 2012-05-16 | 화이자 프로덕츠 인크. | Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체 |
-
2006
- 2006-11-23 DE DE602006018354T patent/DE602006018354D1/de active Active
- 2006-11-23 NZ NZ568654A patent/NZ568654A/en unknown
- 2006-11-23 SI SI200630864T patent/SI1959955T1/sl unknown
- 2006-11-23 CA CA2632286A patent/CA2632286C/en active Active
- 2006-11-23 EP EP06820997A patent/EP1959955B1/en active Active
- 2006-11-23 PL PL06820997T patent/PL1959955T3/pl unknown
- 2006-11-23 US US12/095,114 patent/US7825137B2/en active Active
- 2006-11-23 RU RU2008122471/14A patent/RU2384331C2/ru active
- 2006-11-23 BR BRPI0619424-9A patent/BRPI0619424B1/pt active IP Right Grant
- 2006-11-23 AU AU2006323027A patent/AU2006323027B2/en active Active
- 2006-11-23 KR KR20087016376A patent/KR101026676B1/ko active Active
- 2006-11-23 PT PT06820997T patent/PT1959955E/pt unknown
- 2006-11-23 WO PCT/IB2006/003397 patent/WO2007066187A2/en not_active Ceased
- 2006-11-23 DK DK06820997.2T patent/DK1959955T3/da active
- 2006-11-23 AT AT06820997T patent/ATE488237T1/de active
- 2006-12-04 TW TW095145034A patent/TWI321050B/zh active
- 2006-12-04 JP JP2006327355A patent/JP4619346B2/ja active Active
- 2006-12-05 AR ARP060105369A patent/AR056832A1/es not_active Application Discontinuation
-
2008
- 2008-05-15 IL IL191471A patent/IL191471A/en active IP Right Grant
-
2010
- 2010-11-24 CY CY20101101055T patent/CY1110931T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007066187A3 (en) | 2008-01-17 |
| DK1959955T3 (da) | 2011-02-07 |
| US7825137B2 (en) | 2010-11-02 |
| AR056832A1 (es) | 2007-10-24 |
| PT1959955E (pt) | 2011-01-04 |
| KR101026676B1 (ko) | 2011-04-04 |
| TWI321050B (en) | 2010-03-01 |
| BRPI0619424A2 (pt) | 2011-10-04 |
| JP2007153894A (ja) | 2007-06-21 |
| EP1959955B1 (en) | 2010-11-17 |
| RU2008122471A (ru) | 2009-12-10 |
| KR20080072965A (ko) | 2008-08-07 |
| AU2006323027A1 (en) | 2007-06-14 |
| JP4619346B2 (ja) | 2011-01-26 |
| SI1959955T1 (sl) | 2011-02-28 |
| WO2007066187A2 (en) | 2007-06-14 |
| DE602006018354D1 (de) | 2010-12-30 |
| IL191471A0 (en) | 2009-08-03 |
| IL191471A (en) | 2013-03-24 |
| CA2632286C (en) | 2011-11-15 |
| RU2384331C2 (ru) | 2010-03-20 |
| HK1126121A1 (en) | 2009-08-28 |
| EP1959955A2 (en) | 2008-08-27 |
| ATE488237T1 (de) | 2010-12-15 |
| PL1959955T3 (pl) | 2011-04-29 |
| NZ568654A (en) | 2012-02-24 |
| CA2632286A1 (en) | 2007-06-14 |
| US20080300273A1 (en) | 2008-12-04 |
| BRPI0619424B1 (pt) | 2022-02-08 |
| AU2006323027B2 (en) | 2012-08-02 |
| TW200727899A (en) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110931T1 (el) | Μεθοδος αγωγης της ανωμαλης κυτταρικης αναπτυξεως | |
| TW200730522A (en) | Polymorphs of a C-MET/HGFR inhibitor | |
| FR21C1064I2 (fr) | Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire | |
| MY139942A (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
| NO20076401L (no) | Diarylhydantoinforbindelser | |
| UY33981A (es) | ?método para preparar compuestos macrocíclicos inhibidores de serina proteasas de hepatitis c?. | |
| TW200716141A (en) | Compositions and methods for treatment for neoplasms | |
| TW200714283A (en) | Method and composition for treating peripheral vascular diseases | |
| TW200621715A (en) | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | |
| NZ572251A (en) | Benzimidazole modulators of vr1 | |
| NO20074666L (no) | Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer | |
| TW200720268A (en) | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | |
| NO20083670L (no) | Forbindelser og fremgangsmater for modulering av proteinomsetning | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| UA83875C2 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
| NO20075304L (no) | Metode for avtagende forkalkning | |
| WO2007098099A3 (en) | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | |
| EA201100874A1 (ru) | Соединения для лечения рака | |
| EA201000895A1 (ru) | Композиции и способы для лечения лизосомных болезней | |
| UA90706C2 (ru) | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| WO2007100777A3 (en) | Methods for the treatment of adhd and related disorders | |
| TW200722427A (en) | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | |
| NO20076186L (no) | Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav | |
| ATE437642T1 (de) | Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren |